Active substance
Results for the substance pegunigalsidase alfa
1 result
About this active substance
Pegunigalsidase alfa is a recombinant enzyme used in the treatment of Fabry disease, a rare genetic disorder caused by the accumulation of globotriaosylceramide in cells. It works by replacing the deficient enzyme and reducing substrate accumulation.
The medication is administered intravenously, as directed by a doctor, usually once every two weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as infusion reactions, headaches, or nausea. It is important to inform the doctor of any unusual symptoms.
Common side effects include infusion reactions, headaches, and nausea. In rare cases, severe reactions such as allergic reactions or renal failure may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually once every two weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as infusion reactions, headaches, or nausea. It is important to inform the doctor of any unusual symptoms.
Common side effects include infusion reactions, headaches, and nausea. In rare cases, severe reactions such as allergic reactions or renal failure may occur. Patients should be informed of these risks before use.